Basophil FcεRI expression in chronic spontaneous urticaria: A potential immunological predictor of response to omalizumab therapy.

Deza Vargas, Luis Gustavo; Bertolín Colilla, Marta; Pujol Vallverdú, Ramon Maria; Curto Barredo, Laia; Soto Soto, Dulce; García, Maribel; Hernández, Pilar; Gimeno Martínez, Ramón; Giménez Arnau, Anna Maria

Basophil FcεRI expression in chronic spontaneous urticaria: A potential immunological predictor of response to omalizumab therapy.

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Deza Vargas, Luis Gustavoca
dc.contributor.author Bertolín Colilla, Martaca
dc.contributor.author Pujol Vallverdú, Ramon Mariaca
dc.contributor.author Curto Barredo, Laiaca
dc.contributor.author Soto Soto, Dulceca
dc.contributor.author García, Maribelca
dc.contributor.author Hernández, Pilarca
dc.contributor.author Gimeno Martínez, Ramónca
dc.contributor.author Giménez Arnau, Anna Mariaca
dc.date.accessioned 2017-11-07T11:49:20Z
dc.date.available 2017-11-07T11:49:20Z
dc.date.issued 2017
dc.description.abstract Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment. Such evolution was not observed in non-responder patients. Furthermore, non-responders showed significantly lower baseline levels of FcεRI than responders. Baseline basophil FcεRI expression was found to be a potential immunological predictor of response to omalizumab (100% sensitivity and 73.2% specificity). The results of this study contribute to our knowledge of the therapeutic benefit and mechanism of action of anti-IgE therapy in CSU.
dc.format.mimetype application/pdfca
dc.identifier.citation Deza G, Bertolín-Colilla M, Pujol RM, Curto-Barredo L, Soto D, García M, et al.Basophil FcεRI expression in chronic spontaneous urticaria: A potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017 Jun 9;97(6):698-704. DOI: 10.2340/00015555-2654
dc.identifier.doi http://dx.doi.org/10.2340/00015555-2654
dc.identifier.issn 0001-5555
dc.identifier.uri http://hdl.handle.net/10230/33162
dc.language.iso eng
dc.publisher Society for Publication of Acta Dermato-Venereologicaca
dc.relation.ispartof Acta Dermato-Venereologica. 2017 Jun 9;97(6):698-704
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
dc.subject.other Urticaria
dc.title Basophil FcεRI expression in chronic spontaneous urticaria: A potential immunological predictor of response to omalizumab therapy.ca
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/acceptedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)